Bladder Cancer Detection Videos

Chinese Trial Shows Blue Light Cystoscopy Superior for Bladder Cancer Detection - Hongxian Zhang

Details
Ashish Kamat welcomes Hongxian Zhang to present a phase III study comparing blue light cystoscopy (BLC) with white light cystoscopy (WLC) for bladder cancer detection in China. Conducted across seven hospitals from November 2022 to June 2023, the study involved 158 patients, with 114 remaining in the final analysis. It demonstrates that BLC, especially with Hexaminolevulinate (HAL) and modern 4K L...

Operationalizing Blue Light in Your Practice - Gautam Jayram

Details
Zach Klaassen and Gautam (Tom) Jayram explore the use of blue light cystoscopy in bladder cancer. Dr. Jayram explains its mechanism, where an optical agent, interacting with the heme biosynthetic pathway, causes cancer cells to accumulate photo porphyrins that light up under specific wavelengths. This technology is crucial for patients suspected of having or with a history of bladder cancer, enhan...

An Analysis in NMIBC Patients - A Comparative Study of White Light and Blue Light Cystoscopy in an Equal Access Setting - Stephen B. Williams

Details
Stephen Williams discusses the evolving role of blue light cystoscopy in detecting non-muscle invasive bladder cancer (NMIBC). The conversation covers its pathophysiology, diagnostic and surveillance applications, emphasizing selective utilization and benefits post-BCG therapy. Dr. Williams references a study in Clinical Genitourinary Cancer, sharing insights from a study comparing blue and white...

The Promise, Potential, and Practicality of Cxbladder in Modern Urologic Oncology - Mark Tyson, II

Details
Zach Klaassen hosts Mark Tyson for a discussion on the noninvasive urinary genomic biomarker test, Cxbladder. Dr. Tyson explains that Cxbladder Detect assesses bladder cancer risk in patients with microscopic hematuria by analyzing urine for specific mRNA biomarkers. The test aims to reduce invasive diagnostics like cystoscopy, aligning with AUA guidelines for a risk-stratified approach. Their dec...

Value Based Care in Surveillance of Non-Muscle Invasive Bladder Cancer – Stephen Williams

Details
Stephen Williams joins Ashish Kamat presenting findings on macro and microeconomics of blue light cystoscopy (BLC) with CYSVIEW® in the care of patients with non-muscle invasive bladder cancer, a Urologic Oncology Seminars and Original Investigations publication. The aim of the study was to determine the estimated budget impact to practices that incorporate blue light cystoscopy with hexaminolevul...

Advancing Bladder Cancer Surveillance: The Impact of Flexible Blue Light Cystoscopy from the Nordic Registry - Karsten Zieger

Details
Zach Klaassen is joined by Karsten Zieger to talk about the results of an analysis from the Nordic registry evaluating the role of flexible blue light cystoscopy in the surveillance of non-muscle invasive bladder cancer. Dr. Zieger provides a comprehensive explanation of how blue light cystoscopy works. The method utilizes a photosensitizing agent, Hexvix in Europe or Cysview® in the U.S., that al...

Blue Light Cystoscopy Delays Time To Recurrence in NMIBC Patients Treated in a Real-World Setting - Sia Daneshmand

Details
Sam Chang and Sia Daneshmand explore the impact of Cysview blue light cystoscopy on cancer recurrence. Dr. Daneshmand presents a comprehensive registry study from USC which shows significantly lower recurrence rates in patients examined with blue light cystoscopy, when compared to a white light patient group. Notwithstanding potential variables like modern management techniques, they attribute thi...

Optimal TURBT: Do Skilled Urologists Really Need Photodynamic Diagnosis (PDD)? -Trinity Bivalacqua & Michael Cookson

Details
The 2023 AUA annual meeting included the Bladder Cancer Forum, featuring a debate discussing whether skilled urologists need photodynamic diagnosis (PDD) to perform an optimal TURBT. Drs. Michael Cookson and Trinity Bivalacqua, who were participants in this debate, join Dr. Neal Shore to highlight the takeaways from the session. Cookson argued against the use of blue light due to the limitations a...

The Clinical Benefits of Blue Light Cystoscopy in the Ambulatory Surgical Centers - Neal Shore

Details
Neal Shore joins Alicia Morgans to discuss the benefits of Blue light cystoscopy (BLC) when patients receive this option for bladder cancer care in ambulatory surgery centers. BLC enhances urologists' ability to detect cancerous tissue, leading to more complete resection and reduced costs for the US healthcare system. Reimbursement for outpatient ambulatory surgery centers or clinics could be more...

Reduction in the Risk of Recurrence with the Use of Blue Light Cystoscopy Use Among Patients with Non-Muscle Invasive Bladder Cancer In An Equal Access Setting - Stephen Williams

Details
Sam Chang is joined by Stephen Williams to discuss the impact of Blue Light Cystoscopy (BLC) use among patients with non-muscle invasive bladder cancer (NMIBC) in an equal access setting, specifically the Veterans Affairs (VA) system. Prior studies suggest that white light cystoscopy (WLC) alone can fail to detect cases of NMIBC compared to BLC. Dr. Williams explains that they found a roughly 30%...